journal cover

Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials

Annals of the Rheumatic Diseases

Jul 1, 2017

Stanley B CohenJürgen Wollenhaupt

Get paper from

Abstract

Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We report an integrated safety summary of tofacitinib from two phase I, nine phase II, six phase III and two long-term extension studies in adult patients with active RA. Data were pooled for a...read more

Mentioned in this Paper

Rheumatoid Arthritis
Malignant Neoplasms
Malignant Neoplasm of Skin
Clinical Trials
Communicable Diseases
Herpes Zoster Disease
Opportunistic Infections
Piperidines
Pyrimidines
Pyrroles
10
2
1
118
Paper Details
References
  • References48
  • Citations43
12345
  • References48
  • Citations43
12345

Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials

Annals of the Rheumatic Diseases

Jul 1, 2017

Stanley B CohenJürgen Wollenhaupt

PMID: 28143815

DOI: 10.1136/annrheumdis-2016-210457

Abstract

Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We report an integrated safety summary of tofacitinib from two phase I, nine phase II, six phase III and two long-term extension studies in adult patients with active RA. Data were pooled for a...read more

Mentioned in this Paper

Rheumatoid Arthritis
Malignant Neoplasms
Malignant Neoplasm of Skin
Clinical Trials
Communicable Diseases
10
2
1
118

Related Papers

Paper Details
References
  • References48
  • Citations43
12345
  • References48
  • Citations43
12345

Get paper from

/papers/long-term-safety-of-tofacitinib-for-the-treatment/28143815